Cytosorbents (CTSO) Net Cash Flow Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Cytosorbents | 28.81 Mn | 24.01 Mn | 6.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.92% |
| Dec 31, 2025 | 30.67% |
| Sep 30, 2025 | -15.41% |
| Jun 30, 2025 | -16.97% |
| Mar 31, 2025 | -25.19% |
| Dec 31, 2024 | 9.35% |
| Sep 30, 2024 | -56.64% |
| Jun 30, 2024 | 28.29% |
| Mar 31, 2024 | -15.35% |
| Dec 31, 2023 | 33.36% |
| Sep 30, 2023 | -69.54% |
| Jun 30, 2023 | -27.60% |
| Mar 31, 2023 | -23.08% |
| Dec 31, 2022 | -17.97% |
| Sep 30, 2022 | -48.46% |
| Jun 30, 2022 | -24.33% |
| Mar 31, 2022 | -34.95% |
| Dec 31, 2021 | -45.16% |
| Sep 30, 2021 | -14.63% |
| Jun 30, 2021 | -20.86% |
| Mar 31, 2021 | -11.90% |
| Dec 31, 2020 | -51.01% |
| Sep 30, 2020 | 143.02% |
| Jun 30, 2020 | 40.61% |
| Mar 31, 2020 | 15.41% |
| Dec 31, 2019 | -25.71% |
| Sep 30, 2019 | 41.85% |
| Jun 30, 2019 | -16.69% |
| Mar 31, 2019 | -21.43% |
| Dec 31, 2018 | -96.72% |
| Sep 30, 2018 | -22.71% |
| Jun 30, 2018 | 52.96% |
| Mar 31, 2018 | 65.50% |
| Dec 31, 2017 | 51.59% |
| Sep 30, 2017 | -39.25% |
| Jun 30, 2017 | 193.08% |
| Mar 31, 2017 | -39.41% |
| Dec 31, 2016 | -0.26% |
| Sep 30, 2016 | -15.52% |
| Jun 30, 2016 | 37.72% |
| Mar 31, 2016 | -26.08% |
| Dec 31, 2015 | -55.36% |
| Sep 30, 2015 | -42.68% |